Ke Huang

Represented this entity in its proposed IPO and listing on the Hong Kong Stock Exchange.

Represented these companies in their proposed IPO and listing on the Hong Kong Stock Exchange. These companies focus on various medical fields, including immune-oncology, autoimmune, AIDs, and cardiovascular.

Represented this entity in its proposed IPO and listing on NASDAQ.

Represented underwriters on a private education provider’s proposed IPO on the Hong Kong Stock Exchange. The company was the first company to submit a listing application after “Draft Revision of the Regulations on the Implementation of the Law for Promoting Private Education” was issued by MOJ.

Multiple representations, including: in relation to a technology company’s proposed IPO on the Hong Kong Stock Exchange. The company is a telecom software provider; in relation to the proposed IPO on the Hong Kong Stock Exchange of two game publishing companies and a game developing company.

Represented international underwriters in relation to a telecom software provider’s proposed IPO on the Hong Kong Stock Exchange.

Represented international underwriters in relation to the proposed IPO on the Hong Kong Stock Exchange of two game publishing companies and a game developing company.

Represented three hospital groups in Henan, Hebei, and Guangdong in their proposed IPO on the Hong Kong Stock Exchange.

Represented this financial institution in its IPO and listing on the Hong Kong Stock Exchange.

Represented this entity on its landmark US$1.8 billion Hong Kong IPO, which was the largest IPO in 2013 at the date of listing.

Represented this entity’s debut issuance of a high-yield bond.

Represented underwriters in relation to a Chinese bank’s issue of the AT1 preference shares in three tranches. This issue is the first Asian AT1 offering in three currencies, the first in euros from an Asian bank and the first Asian AT1 offering in Rule 144A/Reg S format. The RMB tranche is also the first offshore RMB denominated AT1 offering and the largest non-sovereign RMB denominated securities offering as of the time of the issuance.

Represented underwriters in relation to a major state-owned asset management company’s US$1 billion dual-tranche bond offering.

Represented a Tianjin-based local government-financing vehicle’s debut bond offering.

Represented this entity on its US$500 million zero-coupon bond exchangeable into the H shares of a Chinese bank. It is the first oversea issuance of an exchangeable bond from a Chinese company.

Represented international underwriters in relation to a major SOE’s concurrent offering of U.S. dollar and euro denominated Notes. The Rule 144A/Reg S US$1.3 billion Notes are the first to feature a full guarantee from China and are the first to be eligible for listing in the emerging market bond index. The Reg S EUR500 million Notes represent the company’s inaugural euro-denominated debt issuance.

Represented international underwriters in relation to the largest U.S. dollar perpetual capital securities offering by an Asian issuer at the time and a EUR1.75 billion euro-denominated perpetual capital securities, which was the first Asian borrower to issue a euro-denominated perpetual.

Represented international underwriters in relation to a Shanghai SOE’s inaugural offshore debt issuance.